PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21983632-4 2011 All hallmarks of photoreceptor apoptosis were prevented by premedication or co-application of Brilliant Blue G, a selective P2RX7 antagonist that is already approved for the staining of internal limiting membranes during ocular surgery. coomassie Brilliant Blue 94-110 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 124-129 20645413-7 2010 Pharmacological and genetic inhibition of P2X7R with brilliant blue G, KN-62, oxATP, and siRNA transfection resulted in a decrease of [(3)H]adenosine uptake, and the uptake was also reduced by low concentration of carbenoxolone and pannexin1 selective peptide blocker (10)panx. coomassie Brilliant Blue 53-69 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 42-47 17175137-3 2007 Incubation with P2X(7) receptor antagonists (KN-62 and Brilliant Blue G) attenuates ATP induced prothrombotic responses. coomassie Brilliant Blue 55-71 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 16-31 19385050-9 2009 Treatment of N2a cells with ATP hydrolase apyrase and the P2X7 receptors selective antagonist oATP or BBG decreased cell viability and cell number. coomassie Brilliant Blue 102-105 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 58-62 18037910-8 2008 The guinea pig P2X(7) receptor possessed higher affinity for 1-[N,O-bis(5-isoquinoline sulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN62), suramin and Coomassie Brilliant Blue than human or rat P2X(7) receptors suggesting that it is pharmacologically different to other rodent or human P2X(7) receptors. coomassie Brilliant Blue 157-181 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 15-30 18082965-6 2008 In addition, P2X(7) inhibitors as ZnSO(4), BBG and suramin abolished partially or totally the responses induced by the physiological agonist ATP. coomassie Brilliant Blue 43-46 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 13-19 34638992-5 2021 In this context, we previously demonstrated that the P2X7 receptor antagonist, brilliant blue G, reduces neuroinflammation and ameliorates some of the pathological features of ALS in the SOD1-G93A mouse model. coomassie Brilliant Blue 79-95 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 53-66 16581969-4 2006 Influx of extracellular Ca2+ was stimulated by ATP and BzATP and inhibited by zinc, Coomassie Brilliant Blue-G, and KN-62, demonstrating activation of P2X7 receptors. coomassie Brilliant Blue 84-110 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 151-155 35254644-3 2022 In COH retinas, the microglial proliferation that occurred was inhibited by the P2X7 receptor (P2X7R) blocker BBG or P2X7R knockout, but not by the P2X4R blocker 5-BDBD. coomassie Brilliant Blue 110-113 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 80-93 35254644-3 2022 In COH retinas, the microglial proliferation that occurred was inhibited by the P2X7 receptor (P2X7R) blocker BBG or P2X7R knockout, but not by the P2X4R blocker 5-BDBD. coomassie Brilliant Blue 110-113 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 95-100 30545568-0 2019 Long-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host disease. coomassie Brilliant Blue 54-70 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 29-42 32471386-2 2020 We, herein, document the role of purinergic P2X7 receptors activation on the third day of UUO, as assessed by means of BBG as its selective inhibitor. coomassie Brilliant Blue 119-122 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 44-58 32471386-3 2020 METHODS: We investigated the effects of brilliant blue G (BBG), a P2X7R antagonist, in the third day of kidney tissue response to UUO in rats. coomassie Brilliant Blue 40-56 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 66-71 32471386-3 2020 METHODS: We investigated the effects of brilliant blue G (BBG), a P2X7R antagonist, in the third day of kidney tissue response to UUO in rats. coomassie Brilliant Blue 58-61 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 66-71 32471386-10 2020 CONCLUSION: BBG, a known highly selective inhibitor of P2X7R, attenuated renal inflammation, collagen synthesis, renal cell apoptosis, and enhanced renal cell proliferation in the early phase of rat model of UUO. coomassie Brilliant Blue 12-15 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 55-60 32170537-2 2020 Pharmacological blockade of P2X7 with Brilliant Blue G can ameliorate disease in SOD1G93A mice, but recent data suggests that this antagonist displays poor penetration of the central nervous system (CNS). coomassie Brilliant Blue 38-54 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 28-32 33734697-4 2021 Before MPTP administration, some mice were given brilliant blue G (BBG), a P2X7R inhibitor. coomassie Brilliant Blue 49-65 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 75-80 33734697-4 2021 Before MPTP administration, some mice were given brilliant blue G (BBG), a P2X7R inhibitor. coomassie Brilliant Blue 67-70 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 75-80 33463682-2 2021 Previous studies revealed that antagonism of the P2X7 receptor with Brilliant Blue G (BBG) reduced liver GVHD but did not alter clinical GVHD in a humanised mouse model. coomassie Brilliant Blue 68-84 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 49-62 33463682-2 2021 Previous studies revealed that antagonism of the P2X7 receptor with Brilliant Blue G (BBG) reduced liver GVHD but did not alter clinical GVHD in a humanised mouse model. coomassie Brilliant Blue 86-89 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 49-62 33005242-2 2020 The anti-inflammatory effect of brilliant blue G (BBG), a specific antagonist of the P2X7R, remains unclear in lipopolysaccharide (LPS)-induced BV-2 cells. coomassie Brilliant Blue 32-48 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 85-90 33005242-2 2020 The anti-inflammatory effect of brilliant blue G (BBG), a specific antagonist of the P2X7R, remains unclear in lipopolysaccharide (LPS)-induced BV-2 cells. coomassie Brilliant Blue 50-53 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 85-90 32566102-6 2020 Similarly, P2X7R inhibition by Brilliant Blue G (BBG) reduced mRNA and protein levels of profibrosis markers, while the P2X7R agonist BzATP accelerated the TGF-beta1-induced CFs activation. coomassie Brilliant Blue 31-47 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 11-16 32566102-6 2020 Similarly, P2X7R inhibition by Brilliant Blue G (BBG) reduced mRNA and protein levels of profibrosis markers, while the P2X7R agonist BzATP accelerated the TGF-beta1-induced CFs activation. coomassie Brilliant Blue 49-52 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 11-16 30528164-5 2019 A740004 and BBG, both P2X7R antagonist, inhibited ATP-induced dye uptake. coomassie Brilliant Blue 12-15 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 22-27 30445307-3 2019 In our study, C57BL/6 mice were intraperitoneally injected with P2X7R antagonists Brilliant Blue G and A438079 from the 4th day to the 10th day during the induction of chronic plus binge alcohol feeding model. coomassie Brilliant Blue 82-98 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 64-69 30063882-4 2018 We examined whether Brilliant Blue G (BBG), a potent non-competitive antagonist of P2X7 receptor, had neuroprotective effects on photoreceptor cell injury in a murine endotoxin-induced uveitis (EIU) model. coomassie Brilliant Blue 20-36 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 83-96 30063882-8 2018 These results indicated that BBG is protective against photoreceptor cell injury in EIU in the mice in vivo, suggesting that P2X7 receptor antagonists may be good candidates for preventing photoreceptor degeneration induced by inflammation. coomassie Brilliant Blue 29-32 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 125-138 30063882-4 2018 We examined whether Brilliant Blue G (BBG), a potent non-competitive antagonist of P2X7 receptor, had neuroprotective effects on photoreceptor cell injury in a murine endotoxin-induced uveitis (EIU) model. coomassie Brilliant Blue 38-41 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 83-96 28930866-8 2017 CONCLUSIONS: P2X7R antagonist OxATP and BBG significantly decreased pancreatic chronic inflammation and fibrosis in a mouse CP model and suggested that blockade of P2X7R-NLRP3 inflammasome signaling pathway may represent a novel therapeutic strategy for CP and its fibrotic process. coomassie Brilliant Blue 40-43 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 164-169 30015007-3 2018 To better understand the role of P2X7R and its subsequent impact on microglial activation, we compared the effect of the P2X7R antagonist Brilliant Blue G (BBG) with that of fluoxetine in an unpredictable chronic mild stress (UCMS) model of depression in mice. coomassie Brilliant Blue 138-154 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 121-126 29572578-12 2018 Furthermore, neutralization of P2RX7 in vivo by BBG suppressed EAU clinically and histopathologically. coomassie Brilliant Blue 48-51 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 31-36 28702712-0 2017 Evaluation of the Anticonvulsant Effect of Brilliant Blue G, a Selective P2X7 Receptor Antagonist, in the iv PTZ-, Maximal Electroshock-, and 6 Hz-Induced Seizure Tests in Mice. coomassie Brilliant Blue 43-59 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 73-86 28702712-6 2017 We aimed to investigate whether P2X7 receptor antagonist-brilliant blue G (BBG)-is able to change seizure threshold in three acute seizure models in mice, i.e., in the intravenous pentylenetetrazole seizure threshold, maximal electroshock seizure threshold and 6 Hz psychomotor seizure threshold tests. coomassie Brilliant Blue 56-73 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 32-45 29084623-8 2017 In addition, the DID model was used to study the effects of the microglia inhibitor minocycline (50 mg/kg/day, 4 days) and purinergic P2X7 receptor antagonist Brilliant Blue G (75 mg/kg/day, 7 days) on alcohol intake. coomassie Brilliant Blue 159-175 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 134-147 28597172-9 2017 Injection of the P2X7 antagonist Brilliant Blue G (BBG) but not A-804598 partly reduced ear swelling compared to vehicle-injected control mice. coomassie Brilliant Blue 33-49 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 17-21 28597172-9 2017 Injection of the P2X7 antagonist Brilliant Blue G (BBG) but not A-804598 partly reduced ear swelling compared to vehicle-injected control mice. coomassie Brilliant Blue 51-54 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 17-21 28665482-0 2017 The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-gamma in a humanized mouse model of graft-versus-host disease. coomassie Brilliant Blue 29-45 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-17 28665482-6 2017 The P2X7 antagonist, Brilliant Blue G (BBG), blocked ATP-induced cation uptake into both murine and human cells in vitro. coomassie Brilliant Blue 21-37 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-8 28665482-6 2017 The P2X7 antagonist, Brilliant Blue G (BBG), blocked ATP-induced cation uptake into both murine and human cells in vitro. coomassie Brilliant Blue 39-42 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-8 28665482-10 2017 In conclusion, the P2X7 antagonist BBG reduced circulating IFN-gamma in a humanized mouse model of GVHD supporting a potential role for P2X7 to alter the pathology of this disease in humans. coomassie Brilliant Blue 35-38 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 19-23 28665482-10 2017 In conclusion, the P2X7 antagonist BBG reduced circulating IFN-gamma in a humanized mouse model of GVHD supporting a potential role for P2X7 to alter the pathology of this disease in humans. coomassie Brilliant Blue 35-38 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 136-140 29070142-1 2017 OBJECTIVE: To investigate the effect of P2X7R antagonist brilliant blue G (BBG) on aGVDH of mice after allo-HSCT. coomassie Brilliant Blue 75-78 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 40-45 28669743-4 2017 Here, we show that P2X7R antagonist Brilliant Blue G (BBG) decreased DNA fragmentation, infarct volume, brain swelling, neurological deficit scores and activation of microglial cells after focal cerebral ischemia. coomassie Brilliant Blue 36-52 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 19-24 28669743-4 2017 Here, we show that P2X7R antagonist Brilliant Blue G (BBG) decreased DNA fragmentation, infarct volume, brain swelling, neurological deficit scores and activation of microglial cells after focal cerebral ischemia. coomassie Brilliant Blue 54-57 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 19-24 28669743-7 2017 These results indicated that inhibition of P2X7R with BBG promoted neuronal survival, not through the activation of survival kinase pathways, but possibly by improved intracellular Ca2+ overload and decreased the levels of Caspase 1, IL-1beta and Bax proteins. coomassie Brilliant Blue 54-57 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 43-48 29070142-2 2017 METHODS: aGVHD mouse model after HSCT was established and treated with the P2X7R antagonist BBG of different dosages (50 mg/kg and 75 mg/kg). coomassie Brilliant Blue 92-95 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 75-80 29070142-4 2017 RESULTS: The allo-HSCT aGVHD mouse model was successfully established, the intraperitoneal injection of BBG alleviated the aGVHD clinical manifestations including roachback, ruffled fur, skin peeling and weight loss of recipient mice, decreased P2X7R and IL-1beta expression and reduced the mRNA levels of P2X7R, NLRP3, Caspase-1, IL-1beta and IL-18. coomassie Brilliant Blue 104-107 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 245-250 29070142-4 2017 RESULTS: The allo-HSCT aGVHD mouse model was successfully established, the intraperitoneal injection of BBG alleviated the aGVHD clinical manifestations including roachback, ruffled fur, skin peeling and weight loss of recipient mice, decreased P2X7R and IL-1beta expression and reduced the mRNA levels of P2X7R, NLRP3, Caspase-1, IL-1beta and IL-18. coomassie Brilliant Blue 104-107 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 306-311 28848393-9 2017 The P2X7 receptor was implicated in the mechanosensitive priming of IL-1beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1beta, and the rise was absent in P2X7 knockout mice. coomassie Brilliant Blue 109-125 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-17 28848393-9 2017 The P2X7 receptor was implicated in the mechanosensitive priming of IL-1beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1beta, and the rise was absent in P2X7 knockout mice. coomassie Brilliant Blue 109-125 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-8 28848393-9 2017 The P2X7 receptor was implicated in the mechanosensitive priming of IL-1beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1beta, and the rise was absent in P2X7 knockout mice. coomassie Brilliant Blue 127-130 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-17 28848393-9 2017 The P2X7 receptor was implicated in the mechanosensitive priming of IL-1beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1beta, and the rise was absent in P2X7 knockout mice. coomassie Brilliant Blue 127-130 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-8 28848393-12 2017 The rise in IL-1beta expression was also blocked by P2X7 receptor antagonists BBG, A839977 or A740003. coomassie Brilliant Blue 78-81 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 52-65 28344198-6 2017 We further examined the radiosensitizing effect of P2X7 receptor antagonist Brilliant Blue G (BBG) in vitro by colony formation assay of B16 cells. coomassie Brilliant Blue 76-92 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 51-64 28344198-6 2017 We further examined the radiosensitizing effect of P2X7 receptor antagonist Brilliant Blue G (BBG) in vitro by colony formation assay of B16 cells. coomassie Brilliant Blue 94-97 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 51-64 28344198-8 2017 BBG pretreatment also decreased the number of DNA repair foci in nuclei, supporting involvement of P2X7 receptor in the DNA damage response. coomassie Brilliant Blue 0-3 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 99-112 28344198-11 2017 Our results suggest that P2X7 receptor antagonist BBG has a radiosensitizing effect in melanoma in vitro and in vivo. coomassie Brilliant Blue 50-53 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 25-38 28244110-10 2017 Intravitreal injection of P2X7 receptor antagonist BBG prevented the pressure-dependent rise in IL-6 mRNA and protein in the rat retina, while injection of P2X7 receptor agonist BzATP was sufficient to elevate IL-6 expression. coomassie Brilliant Blue 51-54 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 26-39 27544305-5 2016 High dose of P2X7R inhibitor administration after HSCT previously reduced levels of IL-1beta, IL-18, caspase-1, NLRP3 as well as P2X7, and the level of alanine transaminase (ALT) and the ratio of aspartate amino transferase (AST)/ALT compared with that receiving low dose of BBG. coomassie Brilliant Blue 275-278 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 13-17 28265522-3 2017 Therefore, the current study aimed to examine P2X7 in the context of neurodegeneration, and investigate whether the P2X7 antagonist, Brilliant Blue G (BBG), could alter disease progression in a murine model of ALS. coomassie Brilliant Blue 133-149 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 116-120 28265522-3 2017 Therefore, the current study aimed to examine P2X7 in the context of neurodegeneration, and investigate whether the P2X7 antagonist, Brilliant Blue G (BBG), could alter disease progression in a murine model of ALS. coomassie Brilliant Blue 151-154 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 116-120 27544305-3 2016 On day 7, 14, 21 and 28 after HSCT, mice received P2X7R antagonist brilliant blue G (BBG) or not were sacrificed for analysis of weight loss, liver inflammation, cytokine secretion, P2X7, NLRP3 expression as well as caspase-1 activation. coomassie Brilliant Blue 67-83 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 50-55 27544305-3 2016 On day 7, 14, 21 and 28 after HSCT, mice received P2X7R antagonist brilliant blue G (BBG) or not were sacrificed for analysis of weight loss, liver inflammation, cytokine secretion, P2X7, NLRP3 expression as well as caspase-1 activation. coomassie Brilliant Blue 67-83 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 50-54 27544305-5 2016 High dose of P2X7R inhibitor administration after HSCT previously reduced levels of IL-1beta, IL-18, caspase-1, NLRP3 as well as P2X7, and the level of alanine transaminase (ALT) and the ratio of aspartate amino transferase (AST)/ALT compared with that receiving low dose of BBG. coomassie Brilliant Blue 275-278 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 13-18 27544305-7 2016 In conclusion, blockage of P2X7R by BBG exerts a protective effect on GVHD post HSCT and improves liver function suggesting that this receptor could be considered as an attractive target for treatment of GVHD. coomassie Brilliant Blue 36-39 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 27-32 26349656-9 2016 Apyrase, an adenosine triphosphate (ATP) scavenger, or Brilliant Blue G, a purinergic P2X7 receptor antagonist, inhibited the damage as well as caspase-1 activation and IL-1beta processing, despite there being sufficient amounts of pro-IL-1beta and NLRP3. coomassie Brilliant Blue 55-71 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 86-99 27531364-6 2016 Western blot and qPCR results showed that the expressions of P2X7 receptor protein and mRNA were positively dose-dependent with gp120 concentration; the results of immunocytochemistry and Western blot showed that the expressions of P2X7 receptor and P65 NF-kappaB in the gp120 group increased significantly compared to those of the control (Ctrl) group, but those in the gp120+BBG group decreased. coomassie Brilliant Blue 377-380 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 61-74 27531364-6 2016 Western blot and qPCR results showed that the expressions of P2X7 receptor protein and mRNA were positively dose-dependent with gp120 concentration; the results of immunocytochemistry and Western blot showed that the expressions of P2X7 receptor and P65 NF-kappaB in the gp120 group increased significantly compared to those of the control (Ctrl) group, but those in the gp120+BBG group decreased. coomassie Brilliant Blue 377-380 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 232-245 24493313-8 2014 iPoCo induced neuroprotective effects were significantly abolished by pretreatment with selective purinergic P2X7 receptor blocker Brilliant Blue G (40 mg/kg intraperitoneal). coomassie Brilliant Blue 131-147 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 109-122 24885962-8 2014 Whereas P2X7 deficiency differentially affected the expression of c-fos, the average number of fos-immuno-reactive neurons in trigeminal nucleus caudalis, but not in upper cervical spinal cord was lower in BBG-treated wild-type mice after NTG treatment. coomassie Brilliant Blue 206-209 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 8-12 26122280-7 2015 Furthermore, blockade of ATP-P2X7R interaction using P2X7 antagonist Brilliant Blue G or P2X7 knockdown suppressed radiation-induced microglial activation and proliferation in the hippocampus, and restored the spatial memory of irradiated mice. coomassie Brilliant Blue 69-85 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 29-34 26122280-7 2015 Furthermore, blockade of ATP-P2X7R interaction using P2X7 antagonist Brilliant Blue G or P2X7 knockdown suppressed radiation-induced microglial activation and proliferation in the hippocampus, and restored the spatial memory of irradiated mice. coomassie Brilliant Blue 69-85 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 29-33 26122280-7 2015 Furthermore, blockade of ATP-P2X7R interaction using P2X7 antagonist Brilliant Blue G or P2X7 knockdown suppressed radiation-induced microglial activation and proliferation in the hippocampus, and restored the spatial memory of irradiated mice. coomassie Brilliant Blue 69-85 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 53-57 25937482-8 2015 Similar results were obtained using another P2X7 inhibitor brilliant blue G (BBG) in vivo. coomassie Brilliant Blue 59-75 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 44-48 25937482-8 2015 Similar results were obtained using another P2X7 inhibitor brilliant blue G (BBG) in vivo. coomassie Brilliant Blue 77-80 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 44-48 23583883-10 2013 We found that (1) the onset and the disease progression, and the survival were dependent on gender: male performed worst than female, lost body weight and died before; (2) treatment with the P2X7 receptor antagonist Brilliant Blue G ameliorated the disease progression. coomassie Brilliant Blue 216-232 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 191-204 24851118-3 2014 The dye brilliant blue G (BBG) is a P2X7R antagonist. coomassie Brilliant Blue 8-24 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 36-41 24851118-3 2014 The dye brilliant blue G (BBG) is a P2X7R antagonist. coomassie Brilliant Blue 26-29 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 36-41 24022661-3 2013 METHODS: MRL/lpr mice were treated with the selective P2X7 antagonist brilliant blue G (BBG) for 8 weeks. coomassie Brilliant Blue 70-86 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 54-58 24022661-8 2013 Blockade of P2X7 activation by BBG suppressed NLRP3/ASC/caspase 1 assembly and the subsequent release of interleukin-1beta (IL-1beta), resulting in a significant reduction in the severity of nephritis and circulating anti-dsDNA antibodies. coomassie Brilliant Blue 31-34 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 12-16 24101734-5 2013 This latter component, which was absent in astrocytes from P2X7 receptor knockout mice (P2X7 KO), was modulated by extracellular Mg(2+), and was sensitive to Brilliant Blue G (BBG) and 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methyl pyridine (A438079) antagonism. coomassie Brilliant Blue 176-179 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 59-72 24101734-6 2013 BzATP also elicited inwardly directed nondesensitizing whole-cell ionic currents that were reduced by extracellular Mg(2+) and P2X7 antagonists (BBG and calmidazolium). coomassie Brilliant Blue 145-148 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 127-131 23770338-4 2013 Removal of extracellular Ca(2+) or application of Brilliant Blue G (BBG), a potent P2X7 receptor (P2X7R) antagonist, protected BV2 microglia from death. coomassie Brilliant Blue 50-66 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 83-96 23770338-4 2013 Removal of extracellular Ca(2+) or application of Brilliant Blue G (BBG), a potent P2X7 receptor (P2X7R) antagonist, protected BV2 microglia from death. coomassie Brilliant Blue 50-66 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 98-103 23770338-4 2013 Removal of extracellular Ca(2+) or application of Brilliant Blue G (BBG), a potent P2X7 receptor (P2X7R) antagonist, protected BV2 microglia from death. coomassie Brilliant Blue 68-71 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 83-96 23770338-4 2013 Removal of extracellular Ca(2+) or application of Brilliant Blue G (BBG), a potent P2X7 receptor (P2X7R) antagonist, protected BV2 microglia from death. coomassie Brilliant Blue 68-71 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 98-103 23770338-7 2013 Indeed, whole cell recordings identified P2X7R-like currents in tissue microglia, and OGD-induced microglial cell death was inhibited by BBG. coomassie Brilliant Blue 137-140 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 41-46 23727220-5 2013 The general P2X/P2Y receptor antagonist PPADS and the P2X7 selective antagonists Brilliant Blue G and A-438079 strongly depressed the effect of Bz-ATP. coomassie Brilliant Blue 81-97 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 54-58 24312160-4 2013 CNTF expression was increased by daily intravenous injections of the P2X7 antagonist Brilliant Blue G (BBG) in naive C57BL/6 or Balb/c mice over 3 days. coomassie Brilliant Blue 85-101 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 69-73 24312160-4 2013 CNTF expression was increased by daily intravenous injections of the P2X7 antagonist Brilliant Blue G (BBG) in naive C57BL/6 or Balb/c mice over 3 days. coomassie Brilliant Blue 103-106 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 69-73 25206704-8 2013 These results suggested that downregulation of the P2X7 receptor by brilliant blue G was involved in the inhibition of microglial activation and inflammation. coomassie Brilliant Blue 68-84 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 51-64 23431238-6 2013 The P2X7 antagonists Brilliant Blue G, A438079, AZ10606120, and AZ11645373 inhibited ATP-induced cation uptake into EOC13 cells by 75-100%. coomassie Brilliant Blue 21-37 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-8 22243662-8 2013 Sub-acute treatment with the selective P2rx7 antagonist, Brilliant Blue G, reproduced the effect of genetic deletion in the TST and AH test in P2rx7(+/+) but not P2rx7(-/-) mice. coomassie Brilliant Blue 57-73 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 39-44 22243662-8 2013 Sub-acute treatment with the selective P2rx7 antagonist, Brilliant Blue G, reproduced the effect of genetic deletion in the TST and AH test in P2rx7(+/+) but not P2rx7(-/-) mice. coomassie Brilliant Blue 57-73 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 143-148 22243662-8 2013 Sub-acute treatment with the selective P2rx7 antagonist, Brilliant Blue G, reproduced the effect of genetic deletion in the TST and AH test in P2rx7(+/+) but not P2rx7(-/-) mice. coomassie Brilliant Blue 57-73 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 143-148 22815977-5 2012 Similarly, brilliant blue G (BBG), a clinically non-toxic P2X7 inhibitor, inhibited IL-1beta expression, limited edemic development, and improved neurobehavioral outcomes after TBI. coomassie Brilliant Blue 11-27 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 58-62 23308196-9 2013 Finally, in a mouse model of subretinal hemorrhage, photoreceptor cells degenerated through BBG-inhibitable apoptosis, suggesting that ligation of P2RX7 by extracellular ATP may accelerate photoreceptor cell apoptosis in AMD with subretinal hemorrhage. coomassie Brilliant Blue 92-95 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 147-152 21794079-8 2012 In dystrophic mice, in vivo treatment with the P2X7 antagonist Coomassie Brilliant Blue reduced the number of degeneration-regeneration cycles in mdx skeletal muscles. coomassie Brilliant Blue 63-87 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 47-51 22733008-7 2012 In mdx/mdx mice treated with Brilliant Blue G, a P2X7 blocker, these blood lymphocytes retained CD62L and were capable of migrating to the heart. coomassie Brilliant Blue 29-45 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 49-53 22815977-5 2012 Similarly, brilliant blue G (BBG), a clinically non-toxic P2X7 inhibitor, inhibited IL-1beta expression, limited edemic development, and improved neurobehavioral outcomes after TBI. coomassie Brilliant Blue 29-32 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 58-62 22815977-7 2012 Notably, P2X7 localized within astrocytic end feet and administration of BBG decreased the expression of glial fibrillary acidic protein (GFAP), a reactive astrocyte marker, and attenuated the expression of aquaporin-4 (AQP4), an astrocytic water channel that promotes cellular edema. coomassie Brilliant Blue 73-76 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 9-13